Substituted 1-phenyl-3-(pyridin-2-yl)urea negative allosteric modulators of mGlu5: Discovery of a new tool compound VU0463841 with activity in rat models of cocaine addiction

ACS Chemical Neuroscience

Volumn 4, Issue 8, 2013, Pages 1217-1228

  Amato, Russell J ^a,b   Felts, Andrew S ^a,b   Rodriguez, Alice L ^a,b   Venable, Daryl F ^a,b   Morrison, Ryan D ^a,b   Byers, Frank W ^a,b   Daniels, J Scott ^a,b   Niswender, Colleen M ^a,b   Conn, P Jeffrey ^a,b   Lindsley, Craig W ^a,b   Jones, Carrie K ^a,b,c   Emmitte, Kyle A ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

addiction; CNS; cocaine; mGlu5; negative allosteric modulator; noncompetitive antagonist

Indexed keywords

COCAINE; METABOTROPIC RECEPTOR 5; UNCLASSIFIED DRUG; UREA DERIVATIVE; VU 0463841; VU0463841;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; COCAINE DEPENDENCE; DRUG ABUSE; DRUG EFFECT; DRUG SEEKING BEHAVIOR; FOLLOW UP; IN VITRO STUDY; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; RELAPSE;

ALLOSTERIC REGULATION; AMINOPYRIDINES; ANIMALS; BRAIN; COCAINE-RELATED DISORDERS; DISEASE MODELS, ANIMAL; LIVER; PHENYLUREA COMPOUNDS; RATS; RECEPTOR, METABOTROPIC GLUTAMATE 5; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 84883210371     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400070k     Document Type: Article

References (59)

1. NIDA Info Facts (2010) Cocaine. National Institute on Drug Abuse, Bethesda, MD. Available online at www.drugabuse.gov/publications/drugfacts/ cocaine.
2. NIDA Research Report Series (2009) Cocaine: abuse and addiction. National Institute on Drug Abuse, Bethesda, MD. Available online at www.drugabuse.gov/ publications/research-reports/cocaine-abuse-addiction.
3. Kalivas, P. W. (2008) Addiction as a pathology in prefrontal cortical regulation of corticostriatal habit circuitry Neurotoxic. Res. 14, 185-189
4. Schoepp, D. D., Jane, D. E., and Monn, J. A. (1999) Pharmacological agents acting at subtypes of metabotropic glutamate receptors Neuropharmacology 38, 1431-1476
5. Conn, P. J. and Pin, J.-P. (1997) Pharmacology and functions of metabotropic glutamate receptors Annu. Rev. Pharmacol. Toxicol. 37, 205-237
6. Melancon, B. J., Hopkins, C. R., Wood, M. R., Emmitte, K. A., Niswender, C. M., Christopoulos, A., Conn, P. J., and Lindsley, C. W. (2012) Allosteric modulation of seven transmembrane spanning receptors: Theory, practice, and opportunities for central nervous system drug discovery J. Med. Chem. 55, 1445-1464
7. Conn, P. J., Christopolous, A., and Lindsley, C. W. (2009) Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders Nat. Rev. Drug Discovery 8, 41-54
8. Bridges, T. M. and Lindsley, C. W. (2008) G-protein coupled receptors: From classical modes of modulation to allosteric mechanisms ACS Chem. Biol. 3, 530-542
9. Ritzén, A., Mathiesen, J. M., and Thomsen, C. (2005) Molecular pharmacology and therapeutic prospects of metabotropic glutamate receptor allosteric modulators Basic Clin. Pharmacol. Toxicol. 97, 202-213
10. 5 negative allosteric modulators: a patent review (2010-2012) Expert Opin. Ther. Pat. 23, 393-408
11. 5 ACS Chem. Neurosci. 2, 411-432
12. Rocher, J. P., Bonnet, B., Boléa, C., Lütjens, R., Le Poul, E., Poli, S., Epping-Jordan, M., Bessis, A.-S., Ludwig, B., and Mutel, V. (2011) mGluR5 negative allosteric modulators overview: A medicinal chemistry approach towards a series of novel therapeutics Curr. Top. Med. Chem. 11, 680-695
13. Lindsley, C. W. and Emmitte, K. A. (2009) Recent progress in the discovery and development of negative allosteric modulators of mGluR5 Curr. Opin. Drug Discovery Dev. 12, 446-457
14. Gasparini, F., Bilbe, G., Gomez-Mancilla, B., and Spooren, W. (2008) mGluR5 antagonists: Discovery, characterization and drug development Curr. Opin. Drug Discovery Dev. 11, 655-665
15. Based on searches performed at www.clinicaltrials.gov on 19 February, 2013.
16. Kenny, P. J., Boutrel, B., Gasparini, F., Koob, G. F., and Markou, A. (2005) Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats Psychopharmacology 179, 247-254
17. Chiamulera, C., Epping-Jordan, M. P., Zocchi, A., Marcon, C., Cottiny, C., Tacconi, S., Corsi, M., Orzi, F., and Conquet, F. (2001) Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice Nat. Neurosci. 4, 873-874
18. Gasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., Varney, M. A., Johnson, E. C., Hess, S. D., Rao, S. P., Sacaan, A. I., Santori, E. M., Veliocelebi, G., and Kuhn, R. (1999) Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systematically active mGlu5 receptor antagonist Neuropharmacology 38, 1493-1503
19. Cosford, N. D., Tehrani, L., Roppe, J., Schweiger, E., Smith, N. D., Anderson, J., Bristow, L., Brodkin, J., Jiang, X., McDonald, I., Rao, S., Washburn, M., and Varney, M. A. (2003) 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]- pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity J. Med. Chem. 46, 204-206
20. Kumaresan, V., Yuan, M., Yee, J., Famous, K. R., Anderson, S. M., Schmidt, H. D., and Pierce, R. C. (2009) Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seeking Behav. Brain Res. 202, 238-244
21. Platt, D. M., Rowlett, J. K., and Spealman, R. D. (2008) Attenuation of cocaine self-administration in squirrel monkeys following repeated administration of the mGluR5 antagonist MPEP: comparison with dizocilpine Psychopharmacology 200, 167-176
22. Lee, B., Platt, D. M., Rowlett, J. K., Adewale, A. S., and Spealman, R. D. (2005) Attenuation of behavioral effects of cocaine by the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: comparison with dizocilpine J. Pharmacol. Exp. Ther. 312, 1232-1240
23. Tessari, M., Pilla, M., Andreoli, M., Hutcheson, D. M., and Heidbreder, C. A. (2004) Antagonism at metabotropic glutamate 5 receptor inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking Eur. J. Pharmacol. 499, 121-133
24. McGeehan, A. J. and Olive, M. F. (2003) The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse Synapse 47, 240-242
25. Wang, X., Moussawi, K., Knackstedt, L., Shen, H., and Kalivas, P. W. (2013) Role of mGluR5 neurotransmission in reinstated cocaine-seeking Addict. Biol. 18, 40-49
26. Martin-Fardon, R., Baptista, M. A. S., Dayas, C. V., and Weiss, F. (2009) Dissociation of the effects of MTEP [3-[(2-methyl-1,3-thiazol-4-yl)ethynyl] pyridine] on conditioned reinstatement and reinforcement: Comparison between cocaine and a conventional reinforcer J. Pharmacol. Exp. Ther. 329, 1084-1090
27. Bäckstrom, P. and Hyytiä, P. (2006) Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking Neuropsychopharmacology 31, 778-786
28. Olsen, C. M., Childs, D. S., Stanwood, G. D., and Winder, D. G. (2010) Operant sensation seeking requires metabotropic glutamate receptor 5 (mGluR5) PLoS One 5, e15085
29. 5 Bioorg. Med. Chem. Lett. 19, 6623-6626
30. Zhou, Y., Rodriguez, A. L., Williams, R., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2009) Synthesis and SAR of novel, non-MPEP chemotype mGluR5 NAMs identified by functional HTS Bioorg. Med. Chem. Lett. 19, 6502-6506
31. Rodriguez, A. L., Williams, R., Zhou, Y., Lindsley, S. R., Le, U., Grier, M. D., Weaver, C. D., Conn, P. J., and Lindsley, C. W. (2009) Discovery and SAR of novel mGluR5 non-competitive antagonists not based on an MPEP chemotype Bioorg. Med. Chem. Lett. 19, 3209-3213
32. 5 NAMs, PAMs and partial antagonists Bioorg. Med. Chem. Lett. 21, 2711-2714
33. 5: Discovery of a new tool compound with activity in the OSS mouse model of addiction ACS Chem. Neurosci. 2, 471-482
34. 5: Identification of easily prepared tool compounds with CNS exposure in rats Bioorg. Med. Chem. Lett. 20, 4390-4394
35. 5): From an artificial neural network virtual screen to an in vivo tool compound ChemMedChem 7, 406-414
36. Sharma, S., Rodriguez, A. L., Conn, P. J., and Lindsley, C. W. (2008) Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold Bioorg. Med. Chem. Lett. 18, 4098-4101
37. Rodriguez, A. L., Nong, Y., Sekaran, N. K., Alagille, D., Tamagnan, G. D., and Conn, P. J. (2005) A close structural analogue of 2-methyl-6- (phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effect of multiple allosteric modulators Mol. Pharmacol. 68, 1793-1802
38. Raboisson, P., Breitholtz-Emanuelsson, A., Dahllöf, H., Edwards, L., Heaton, W. L., Isaac, M., Jarvie, K., Kers, A., Minidis, A. B. E., Nordmark, A., Sheehan, S. M., Slassi, A., Ström, P., Terelius, Y., Wensbo, D., Wilson, J. M., Xin, T., and McLeod, D. A. (2012) Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development Bioorg. Med. Chem. Lett. 22, 6974-6979
39. Kulkarni, S. S., Zou, M.-F., Cao, J., Deschamps, J. R., Rodriguez, A. L., Conn, P. J., and Newman, A. H. (2009) Structure-activity relationships comparing N -(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted- arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists J. Med. Chem. 52, 3563-3575
40. Milbank, J. B. J., Knauer, C. S., Augelli-Szafran, C. E., Sakkab-Tan, A. T., Lin, K. K., Yamagata, K., Hoffman, J. K., Zhuang, N., Thomas, J., Galatsis, P., Wendt, J. A., Mickelson, J. W., Schwarz, R. D., Kinsora, J. J., Lotarski, S. M., Stakich, K., Gillespie, K. K., Lam, W. W., and Mutlib, A. E. (2007) Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists Bioorg. Med. Chem. Lett. 17, 4415-4418
41. Tehrani, L. R., Smith, N. D., Huang, D., Poon, S. F., Roppe, J. R., Seiders, T. J., Chapman, D. F., Chung, J., Cramer, M., and Cosford, N. D. P. (2005) 3-[Substituted]-5-(5-pyridin-2-yl-2 H -tetrazol-2-yl)benzonitriles: Identification of highly potent and selective metabotropic glutamate subtype 5 receptor antagonists Bioorg. Med. Chem. Lett. 15, 5061-5064
42. Hamill, T. G., Krause, S., Ryan, C., Bonnefous, C., Govek, S., Seiders, T. J., Cosford, N. D. P., Roppe, J., Kamenecka, T., Patel, S., Gibson, R. E., Sanabria, S., Riffel, K., Eng, W., King, C., Yang, X., Green, M. D., O'Malley, S. S., Hargreaves, R., and Burns, H. D. (2005) Synthesis, characterization, and first successful monkey imaging studies of metabotropic monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers Synapse 56, 205-216
43. Kalvass, J. C. and Maurer, T. S. (2002) Influence of non-specific brain and plasma binding on CNS exposure: implications for rational drug discovery Biopharm. Drug Dispos. 23, 327-338
44. 5 PAM Bioorg. Med. Chem. Lett. 22, 3921-3925
45. Jones, C. K., Bubser, M., Thompson, A. D., Dickerson, J. W., Turle-Lorenzo, N., Amalric, M., Blobaum, A. L., Bridges, T. M., Morrison, R. D., Jadhav, S., Engers, D. W., Italiano, K., Bode, J., Daniels, J. S., Lindsley, C. W., Hopkins, C. W., Conn, P. J., and Niswender, C. M. (2012) The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease J. Pharmacol. Exp. Ther. 340, 404-421
46. Niswender, C. M., Johnson, K. A., Miller, N. R., Ayala, J. E., Luo, Q., Williams, R., Saleh, S., Orton, D., Weaver, C. D., and Conn, P. J. (2010) Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7 Mol. Pharmacol. 77, 459-468
47. LeadProfilingScreen, Eurofins Panlabs, Inc. (http://www.eurofinspanlabs. com).
48. Kasanetz, F., Lafourcade, M., Deroche-Gamonet, V., Revest, J.-M., Berson, N., Balado, E., Fiancette, J.-F., Renault, P., Piazza, P.-V., and Manzoni, O. J. (2013) Prefrontal synaptic markers of cocaine addiction-like behavior in rats Mol. Psychiatry 18, 729-737
49. Kalivas, P. W. and Volkow, N. D. (2005) The neural basis of addiction: a pathology of motivation and choice Am. J. Psychiatry 162, 1403-1413
50. Phillips, A. G., Ahn, S., and Howland, J. G. (2003) Amygdalar control of the mesocorticolimbic dopamine system: parallel pathways to motivated behavior Neurosci. Biobehav. Rev. 27, 543-554
51. Everitt, B. J., Cardinal, R. N., Parkinson, J. A., and Robbins, T. W. (2003) Appetitive behavior: impact of amygdala-dependent mechanisms of emotional learning Ann. N.Y. Acad. Sci. 985, 233-250
52. Wise, R. A. (1998) Drug-activation of brain reward pathways Drug Alcohol Depend. 51, 13-22
53. Heidbreder, C. (2011) Advances in animal models of drug addiction Curr. Top. Behav. Neurosci. 7, 213-250
54. Tzschentke, T. M. (2007) Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade Addict. Biol. 12, 227-462
55. Rutten, K., van der Kam, E. L., De Vry, J., Bruckman, W., and Tzschentke, T. M. (2011) The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates conditioned place preference induced by various addictive and non-addictive drugs in rats Addict. Biol. 16, 108-115
56. 5 receptor antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) supports intravenous self-administration and induces conditioned place preference in the rat Eur. J. Pharmacol. 607, 114-120
57. Thomsen, M. and Caine, S. B. (2005) Chronic intravenous drug self-administration in rats and mice. Curr. Protoc. Neurosci. chapter 9, unit 9.20.
58. Prus, A. J., James, J. R., and Rosecrans, J. A. (2009) Conditioned Place Preference. In Methods of Behavior Analysis in Neuroscience (Buccafusco, J. J., Ed.), 2 nd ed., CRC Press, Boca Raton, FL.
59. Calcagnetti, D. J. and Schechter, M. D. (1994) Nicotine place preference using the biased method of conditioning Prog. Neuropsychopharmacol. Biol. Psychiatry 18, 925-933